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Purpose: To describe the visual acuity and safety outcomes for the first 50 patients with 
  neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields 
Eye Hospital.
Methods: A retrospective analysis of case notes from the first 50 consecutive patients with 
Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and 
adverse events were noted, as were service delivery-related indicators.
Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The 
mean follow-up of patients was 13.6 ± 2 (range 7.7–18) months. The mean change in visual 
  acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 
15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. 
The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior 
to the final appraisal document from the National Institute of Health and Clinical Excellence.
Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients 
with nAMD are comparable with those reported in the pivotal, randomized, controlled trials 
using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.
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Introduction
Ranibizumab (Lucentis®; Novartis, Basel, Switzerland) therapy has transformed the 
treatment of choroidal neovascularization due to age-related macular   degeneration, 
ie, neovascular AMD (nAMD). Licensed for use by the European Medicines Agency 
in 2006, ranibizumab is an affinity-matured monoclonal antibody fragment which 
binds to and blocks the action of all isoforms of vascular endothelial growth fac-
tor and is administered by four-weekly intravitreal injection. The pivotal Phase III 
  studies used a continuous dosing strategy.1,2 However, the resource and patient bur-
den of monthly injections led clinicians to investigate other treatment strategies. The 
PrONTO   (Prospective Optical Coherence Tomography Imaging of Patients with 
Neovascular AMD Treated with intraOcular Ranibizumab) study was a prospective, 
open-label study in which patients with subfoveal choroidal neovascularization and 
a minimum optical coherence tomography (OCT) retinal thickness of 300 µm were 
given three injections of ranibizumab on a monthly basis, with further retreatment 
based on physician-driven, OCT-guided retreatment criteria using monthly follow-up.3,4 
Patients were still   followed up every four weeks in this study. This treatment strategy 
was also used by the National Institute of Health and Clinical Excellence (NICE) 
when determining the cost-effectiveness of ranibizumab therapy, with an average Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of six injections in the first year of therapy. Although the 
PrONTO study followed up patients on a four-weekly cycle, 
an alternative approach is the “inject and extend” strategy5 in 
which the interval between patient visits is increased in the 
absence of disease activity, with retreatment based on OCT 
criteria. However, there are very few reports of outcomes of 
ranibizumab therapy using prn strategies in clinical practice, 
and it remains unclear how the outcomes of clinical trials 
relate to outcomes in clinical practice.
Because continuous four-weekly review of patients as per 
clinical trial paradigms may not be practical or achievable 
for all elderly patients with nAMD, it is important to report 
real-life outcomes of ranibizumab therapy for patients in the 
clinic. The provision of ranibizumab funding from Primary 
Care Trusts (PCTs) in England and Wales was on a case-
by-case basis prior to definitive NICE guidance. This led to 
delays in treatment resulting from funding delays and service 
provision-related factors. This retrospective case series also 
provided an opportunity to report key outcome measures in 
service delivery which may be used to generate benchmark 
indicators of service delivery and quality for the delivery of 
nAMD treatment services.
There is therefore a need to report outcomes of ranibi-
zumab therapy for nAMD in clinical practice. The aim of 
this study was to report outcomes of ranibizumab therapy 
in the first cohort of patients funded for the drug at a large 
London teaching hospital, and reporting both visual acuity 
outcomes and service provision-related outcomes.
Materials and methods
This was a retrospective case note review of the first 
50 patients with PCT funding for ranibizumab therapy at 
Moorfields Eye Hospital. Applications to the PCTs for 
ranibizumab funding were made if the lesion character-
istics and visual acuity of the eye being considered for 
treatment fulfilled the inclusion and exclusion criteria for 
the ANCHOR   (ANti-VEGF Antibody for the Treatment 
of Predominantly Classic CHORoidal Neovascularization 
in AMD) and MARINA (Minimally classic/occult trial of 
the Anti-VEGF antibody Ranibizumab In the treatment of 
Neovascular AMD) Phase III trials at the time of initial 
funding application. However, patients differed from the 
pivotal ranibizumab trials in that many had received previ-
ous treatment for nAMD (including antivascular endothelial 
growth factor therapy). The decision to apply for funding 
was determined on a case-by-case basis at weekly consul-
tant meetings. Any delays in funding and treatment may 
lead to a change in lesion composition, with the potential 
for subretinal fibrosis or retinal pigment epithelium atrophy 
to compromise outcomes. Patients were identified from the 
funding database and case notes were obtained to confirm the 
diagnosis. If both eyes had obtained funding for treatment, 
the first eye undergoing treatment was included. Patients 
included in this study predated the definitive NICE appraisal 
document issued in August 2008. We included patients with 
previous treatment in this cohort as a representative case mix 
of our initial experience.
The date of the initial funding application, notification 
of successful funding, and dates of patient visits were all 
noted. The angiographic classification of the choroidal 
neovascularization was also noted from the patient notes, 
as was whether a ranibizumab injection was given at each 
visit. Visual acuity at each visit was noted as an ETRS (Early 
Treatment of Diabetic Retinopathy) score, as were any ocu-
lar or systemic adverse events. OCT was performed at each 
visit and prn treatment based on OCT-guided retreatment 
criteria (PrONTO study) was carried out. The development 
of subretinal fibrosis, retinal pigment epithelium atrophy, 
macular hemorrhage, or a retinal pigment epithelium tear 
was noted by the treating ophthalmologist because these may 
compromise visual acuity outcomes.
statistical analysis
Visual acuity results are reported as mean and median val-
ues using the Student’s t-test and Wilcoxon signed-rank test 
to compare values. The influence of previous treatment on 
mean and median visual acuity change was also examined. 
Correlations between variables were assessed using both the 
Pearson correlation and Spearman nonparametric   correlation 
analyses.
The influence of baseline visual acuity on the number 
of injections over 12 months (calculated from the number 
of reinjections received and the follow-up duration) was 
assessed, as was the influence of the number of injections 
per 12 months on visual acuity outcomes. In addition, the 
correlation between visual acuity change and duration of 
follow-up was also examined with a scatter plot and both the 
Pearson correlation and Spearman nonparametric   correlation 
analyses.
Results
Data from 50 eyes of 50 patients were available for analysis. 
There were 30 (60%) females and 20 (40%) males. The mean 
(± standard deviation) age of patients was 80 ± 17 years, with 
26 (54%) being right eyes and 24 (48%) left eyes. There were 
five eyes with classic no occult or predominantly classic Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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lesions and 45 eyes with minimally classic lesions or occult 
no classic lesions. Twenty-eight eyes (56%) had received 
previous treatment for nAMD (12 eyes [24%] had received 
bevacizumab intravitreal injection and 16 eyes [32%] had 
received photodynamic therapy). The mean and median 
interval for ranibizumab funding approval from PCTs was 
35 days and 32 days, respectively. At baseline (prior to ranibi-
zumab therapy), the mean and median visual acuity ETDRS 
letter scores were 46 (6/38) and 50 (6/30), respectively. The 
initial treatment paradigm used was three injections then prn 
in 28 eyes (56%), two injections then prn in 18 eyes (36%), 
and one injection then prn in four eyes (8%). There were 
outcome differences in the three groups, with a trend for 
better outcomes with three injections + prn (mean +8.3 let-
ter gain in this group versus +0.8 letters in 2 + prn and -3.8 
letters in 1 + prn). However, it is difficult to draw definitive 
conclusions about the merits of the three injections + prn 
dosing schedule because most patients on the other two 
dosing schedules had received previous treatment and were 
more likely to have more chronic lesions. Furthermore, the 
subgroups were small in number.
The mean and median number of visits was 11 ± 2.3 
and 10 (range 6–15), respectively, with a mean and median 
follow-up duration of 13.6 ± 2.5 (range 7.7–18) months. For 
the 37 eyes of 37 patients (74%) with 12 months or more of 
follow-up, the mean number of visits in the initial 12-month 
treatment period was 9.8. There were 28 patients who had 
received previous treatment for nAMD in the index eye, 
and this modified the need for the initiation of ranibizumab 
therapy, with some patients not needing immediate treat-
ment due to stabilization of nAMD, leading to an increase 
in the interval between funding approval and treatment. For 
the 22 patients with no previous treatment, the mean and 
median delay in the first ranibizumab injection after funding 
was obtained was 21 days and 20 days, respectively. There 
were nine patients of the 22 (41%) who received treatment 
in two weeks or less, with four patients waiting longer than 
one month after PCT funding approval notification.
During the course of treatment, there was an improve-
ment in the mean and median visual acuity scores of +4.6 
letters (Student’s t-test, t = 2.07, P = 0.04) and +5 letters 
(  Wilcoxon signed-rank test, z = -1.96; P = 0.05), respec-
tively.   Figure 1 shows the distribution of visual acuity change 
for this cohort of patients. Table 1 summarizes the visual 
acuity outcomes both at six months and at final follow-up.
Of note, 42 patients (84%) lost less than 15 letters 
(three lines) of visual acuity (95% confidence interval [CI]: 
79%–89%) and 13 patients (26%) gained 15 letters or more 
in visual acuity (95% CI: 14%–38%) at the end of follow-up. 
The reasons for vision loss of 15 letters or more in the eight 
patients were development of subfoveal/subretinal fibrosis 
in four patients, and geographic atrophy in two patients. 
The reason for vision loss in the remaining two patients was 
not listed.
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The visual acuity outcomes were obtained with a mean 
and median number of treatments of 5.3 ± 2.5 and 5.0, 
respectively, over the total follow-up period. When the 
number of treatments was standardized for the duration of 
follow-up, this equated to a mean and median number of 
treatments per year of 4.7 ± 1.9 and 4.5, respectively. For 
the 37 patients with at least one year of follow-up, the mean 
and median numbers of treatments per year were 4.7 ± 2.1 
and 4.5, respectively.
No correlation was found between number of injections 
over 12 months and baseline visual acuity (Pearson, r = 0.06; 
P = 0.70; Spearman, r = 0.05; P = 0.74). We did not carry 
out an analysis of the correlation between baseline lesion 
angiographic subtype and number of treatments because 
there were too few classic no occult or predominantly clas-
sic lesions to permit a meaningful analysis. No correlation 
was found between number of injections over 12 months and 
change in visual acuity at final follow-up (Pearson, r = 0.18; 
P = 0.21; Spearman, r = 0.06; P = 0.70). In addition, as 
  Figure 2   demonstrates, no correlation was found between 
change in visual acuity and length of follow-up (Pearson, 
r = 0.17; P = 0.25; Spearman, r = 0.09; P = 0.54).
The mean change in visual acuity in 28 patients who had 
received previous treatment was +2.8 letters compared with 
a mean gain of +6.9 letters in 22 patients with no previous 
treatment (Student’s t-test, P = 0.36). The median change in 
visual acuity in patients who had received previous   treatment 
was +7.5 letters compared with a gain of +5.0 letters in 
patients with no previous treatment (Wilcoxon rank-sum 
test, P = 0.82).
Adverse events
Ranibizumab therapy was well tolerated in this cohort of 
patients, with no reports of endophthalmitis, traumatic 
cataract, or retinal detachment. In addition, there were no 
thromboembolic events reported in this cohort of patients 
during follow-up.
Discussion
This report describes the outcome of ranibizumab therapy 
in the first cohort of patients funded for treatment at a ter-
tiary care centre in the UK. These patients were treated at 
a time before the publication of NICE guidance   regarding 
  ranibizumab and pegaptanib therapy, when funding of 
therapy by Primary Care Trusts was problematic and often 
at the discretion of an exceptional case panel. This led to 
delays in treatment which were compounded by the lack 
of capacity for intravitreal treatment. Despite these bar-
riers to treatment and optimal outcomes, the results are 
comparable with the outcomes seen in the pivotal Phase 
III trials of ranibizumab.1,2 The treatment strategy adopted 
in the randomized controlled trials was one of continuous 
therapy but, in view of the patient- and resource-intensive 
nature of monthly intravitreal injection, investigators have 
used a modified treatment strategy with monthly visits but 
with three loading doses and further prn treatment based on 
OCT-guided retreatment criteria (PrONTO study).3 Two-year 
data are now available for this treatment strategy, suggesting 
comparable results with continuous dosing but with a mean 
number of treatments of 5–6 per year of follow-up, with 
monthly visits.4 Others have described an inject and extend 
model in which the follow-up interval after the three-monthly 
loading injections was modified and extended if disease 
quiescence was achieved.5 The advantage of this approach 
is to reduce the number of visits to the hospital eye clinic, 
an important consideration in this group of elderly patients 
with other comorbidity. Given the resource limitations and 
the disease burden, although ophthalmologists in the UK at 
the beginning of ranibizumab therapy started with a fixed 
monthly review interval as per the PrONTO study, the 
Table 1 summary of visual acuity outcomes
Visual acuity outcomes At 6 months At final follow-up
Mean change (se) +6.4 (±1.4) +4.6 (±0.7)
Median change  +5 +5
number of patients (%)
  Losing less than 15 letters 48 (96%) 42 (84%)
  Losing less than 10 letters 45 (90%) 40 (80%)
    Avoiding any loss of visual 
acuity ($0 letter change)
44 (88%) 37 (74%)
  gaining 10 letters or more 21 (42%) 24 (48%)
  gaining 15 letters or more 14 (28%) 13 (26%)
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Figure 2 Plot of change in visual acuity against length of follow-up.Clinical Ophthalmology
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pressures of service delivery and patient comorbidity led 
to an   increasing number of patients funded for treatment 
potentially receiving less frequent follow-up, shifting to a 
more treat and extend approach. Our cohort reflects this 
shift only to a limited degree because the mean and median 
patient visits in 12 months were approximately 10, suggest-
ing reasonably close follow-up of patients, without much 
extension in follow-up interval. This may go some way to 
explaining the good outcomes we report.
In this study, we found no relationship between baseline 
visual acuity or the number of injections and visual acuity 
gain. This may reflect the fact that patients with poor baseline 
visual acuity may have had previous treatment with subretinal 
fibrosis or atrophy. The scatter plot (Figure 2) and the analy-
ses performed show no correlation between change in visual 
acuity and length of follow-up in this cohort, suggesting no 
fall-off in visual acuity gains with increased follow-up.
Our results contrast with those from another recent ret-
rospective study by Cohen et al from a tertiary care center in 
France.6 We report a mean gain in visual acuity (+4.6 letters) 
while the previous study reported only stabilization in visual 
acuity (mean gain of 0.7 letters). Both the previous study and 
our report describe real-world use of ranibizumab in different 
health care settings. Although there were potentially more 
delays in treatment for the cohort of patients we describe, 
in view of the delay in authorizing funding for ranibizumab 
therapy from PCTs, our outcomes appear better than those 
reported by Cohen et al. This may be in view of the larger 
number of treatments and the closer follow-up of patients 
in our series.
Because there are difficulties in directly translating the 
results from clinical trials into clinical practice, it is reassur-
ing to report outcomes in this cohort of patients not dissimilar 
to those in the Phase III ranibizumab studies. Further work 
is needed to determine whether more prompt treatment may 
improve outcomes. In this study we describe benchmark 
indicators of service delivery, including the time from PCT 
funding to treatment. The Royal College of Ophthalmologists 
recommends a diagnosis to treatment time of up to two weeks, 
and indeed 14 days was the duration of the   screening 
period for patients included in the randomized controlled 
  ranibizumab trials. We report positive outcomes, despite 
only 41% of patients receiving treatment within 14 days of 
funding, with a mean delay of 35 days in obtaining funding 
for therapy from the PCTs.
The limitations of this study include its retrospective 
nature and the nonstandardized follow-up or retreatment 
strategy, although this may also be viewed as a potential 
advantage, reflecting real-world use of this agent prior to 
NICE guidance. The advantages include the report of real-
world outcome data for the use of ranibizumab in the treat-
ment of nAMD with additional data regarding the time taken 
to start therapy and the use of standardized visual acuity mea-
surement in assessing outcomes. Further studies are needed to 
determine what factors are most important in achieving good 
outcomes in clinical practice. In summary, this is the first 
study to report positive outcomes for the use of ranibizumab 
in the treatment of nAMD in a clinical setting.
Disclosure
AT has been on the advisory boards for the following com-
panies involved in research or products related to the treat-
ment of retinal disorders: Novartis, Pfizer, GSK, MSD, and 
Allergan. PP has received travel grants from Novartis. The 
other authors report no competing interests in this work.
References
1.  Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verte-
porfin for neovascular age-related macular degeneration. N Engl J Med. 
2006;355:1432–1444.
2.  Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular 
age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
3.  Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence 
tomography-guided, variable dosing regimen with intravitreal ranibi-
zumab (Lucentis) for neovascular age-related macular degeneration. 
Am J Ophthalmol. 2007;143:566–583.
4.  Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regi-
men with intravitreal ranibizumab for neovascular age-related macular 
degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148: 
43–58.
5.  Spaide R. Ranibizumab according to need: A treatment for age-related 
macular degeneration. Am J Ophthalmol. 2007;143:679–680.
6.  Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year’s treatment 
with ranibizumab for exudative age-related macular degeneration in 
a clinical setting. Am J Ophthalmol. 2009;148:409–413.